For most of the past decade, investors have been badly burned by
energy-tech and bio-whatever. In many cases, investors bought into bad
business models that were built more on hype than sound economic
principles. Yet, throughout that time, ethanol and biodiesel use has
continued to grow and the U.S. government has continued to encourage
(and in many cases, mandate) increased use of these fuels.
That leaves the very small FutureFuel (FF)
as an interesting, albeit very risky, stock to consider. Not only does
FutureFuel have a real biodiesel plant up and running, but it uses a
different feedstock than most if its competitors. FutureFuel also has a
specialty chemical business that not only offsets some of the volatility
of the biodiesel business, but also offers growth prospects in its own
right.
Continue to the full article here:
FutureFuel Looks Undervalued, But Mind The Volatility
Showing posts with label Solazyme. Show all posts
Showing posts with label Solazyme. Show all posts
Friday, December 21, 2012
Thursday, November 10, 2011
Investopedia: Solazyme May Pay Off On Green Dreams
As embarrassingly high-profile green company bankruptcies, in recent weeks, have reminded investors that governments may be poor at picking long-term winners, it is also worth repeating that it's not easy being green. Conventional methods of producing energy are cheap, easy and reliable, and those are high hurdles for new technologies to surmount. Nevertheless, while there is ample uncertainty left, Solazyme (NASDAQ: SZYM) is a green-tech company with technology well-worth a look from aggressive investors.
Quarterly Results are Trivial
In the larger scheme of things, Solazyme's quarterly earnings reports don't matter much right now because, frankly, there are no earnings. Solazyme did announce that revenue rose 93% from last year, but with total revenue still below $9 million, it's not all that significant. Likewise the GAAP net loss of $14 million is not so significant.
Follow this link for the full piece:
http://stocks.investopedia.
Quarterly Results are Trivial
In the larger scheme of things, Solazyme's quarterly earnings reports don't matter much right now because, frankly, there are no earnings. Solazyme did announce that revenue rose 93% from last year, but with total revenue still below $9 million, it's not all that significant. Likewise the GAAP net loss of $14 million is not so significant.
Follow this link for the full piece:
http://stocks.investopedia.
Subscribe to:
Posts (Atom)